Logo Logo
Switch Language to German
Herring, Arne; Münster, Yvonne; Akkaya, Tamer; Moghaddam, Sahar; Deinsberger, Katharina; Meyer, Jakob; Zahel, Julia; Sanchez-Mendoza, Eduardo; Wang, Yachao; Hermann, Dirk M.; Arzberger, Thomas; Teuber-Hanselmann, Sarah; Keyvani, Kathy (2016): Kallikrein-8 inhibition attenuates Alzheimer's disease pathology in mice. In: Alzheimers & Dementia, Vol. 12, No. 12: pp. 1273-1287
Full text not available from 'Open Access LMU'.


Introduction: Memory loss and increased anxiety are clinical hallmarks of Alzheimer's disease (AD). Kallikrein-8 is a protease implicated in memory acquisition and anxiety, and its mRNA is known to be up-regulated in AD-affected human hippocampus. Therefore, an involvement of Kallikrein-8 in Alzheimer's pathogenesis is conceivable but remains to be proved. Methods: We determined the cerebral expression of Kallikrein-8 mRNA and protein during the course of AD in patients and in transgenic mice and tested the impact of Kallikrein-8 inhibition on AD-related pathology in mice and in primary glial cells. Results: Kallikrein-8 mRNA and protein were up-regulated in both species at incipient stages of AD. Kallikrein-8 inhibition impeded amyloidogenic amyloid-precursor-protein processing, facilitated amyloid (A beta) clearance across the blood-brain-barrier, boosted autophagy, reduced A beta load and tau pathology, enhanced neuroplasticity, reversed molecular signatures of anxiety, and ultimately improved memory and reduced fear. Discussion: Kallikrein-8 is a promising new therapeutic target against AD. (C) 2016 The Authors. Published by ELSEVIER. on behalf of the Alzheimer's Association. This is an open access article under the CC BY-NC-ND license.